Vaccination anti-HPV et risque de maladies auto-immunes : étude de cohorte française

Miranda, S.; Chaignot, C.; Collin, C.; Dray‐Spira, R.; Weill, Alain; Zureik, Mahmoud

doi:10.1016/j.respe.2016.01.037

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…6 An unpublished cohort study in France has suggested an increased risk of Guillain-Barr e syndrome, which was not seen in other studies such as a cohort study in Finland of potential immune mediated reactions and requires confirmation in further studies. 7,8 It was useful to collect safety data throughout this study though the primary objectives were immunological. The original paper 2 reported higher moderate/ severe tenderness for Cervarix Ò , but comparable reporting for the other local and general reactions recorded.…”

Section: Introductionmentioning

confidence: 99%

Reactogenicity of Cervarix and Gardasil human papillomavirus (HPV) vaccines in a randomized single blind trial in healthy UK adolescent females

Haskins-Coulter

Southern

Andrews

et al. 2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies. Local and systemic events were rarely of high severity, except for tenderness at the injection site which reached a severe level after at least one of the doses in 24% of the Cervarix® group and 7% of the Gardasil® group (p = 0.001 comparing groups). For most reactions, no dose response was recorded, except for swelling with higher reporting at dose 3 (17.7%) than dose 1 (3.1%) for Cervarix®. SAE reporting was low (n = 3) and considered unrelated to either vaccine. This paper supports the body of evidence that Gardasil® has an acceptable safety profile when compared with Cervarix® and other vaccines given in the national program.

show abstract

Section: Introductionmentioning

confidence: 99%